euro adhoc: Marseille-Kliniken AG
Financial Figures/Balance Sheet
- Revenues
extended to EUR 214.8 million in financial year 2006/2007
- Gains per share DVFA/SG increased by EUR 0.10 to EUR 0.86
- Significant revenue and sales growth anticipated ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
annual report
10.10.2007
Berlin, October 10., 2007. Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, and MKA) continues to grow and improves its result. On the basis of preliminary and audited figures for the fiscal year 2006/07, the Marseille-Kliniken AG was able to expand revenues to EUR 214.8 million (previous year: EUR 210.4 million). The group´s annual surplus based on minority shares climbed from EUR 8.9 million to EUR 9.1 million. This translates into a per- share profit of EUR 0.75 compared to EUR 0.73 in the year prior. The EBIT came in at EUR 23.6 million. In 2005/06 it had been at a level of EUR 25.8 million. The EBITDAR result was 69.8 million Euro in the financial year compared to 66.7 million Euro the previous year. The balance sheet reported equity capital totals EUR 71.2 million instead of last year´s EUR 66.8 million so that the equity capital quota is now 23.0 % (year prior 20.7 %).
The DVFA/SG (IFRS) adjusted result this reporting period came in at EUR 10.5 million versus EUR 9.3 million last year. Per share, this equals a profit increase of EUR 0.10 to EUR 0.86 (2005/06 = EUR 0.76). Compared to last year´s EUR 58.0 million, the EBITDAR could be increased to EUR 61.8 million and the EBIT to EUR 20.2 million (year prior: EUR 19.4).
The care sector operated 53 facilities with a bed capacity of 7,287 (previous year 7,134 beds) by the end of the year. Its revenues were extended from EUR 162.7 million to 166.5 million during the reporting period. Due to a one-time special tax impact in the amount of EUR 0.5 million, which resulted from the sale and lease back transaction, the DVFA result declined slightly from EUR 12.9 million in 2005/06 to EUR 12.7 million. On par with the forecast, bed capacity utilization could be continuously expanded per quarter from last year´s average 91.6 %. to an average of 92.8 % by the the fiscal year. The total bed capacity of the group was expanded to 8,765 beds. Group capacity utilization outperformed last year´s and rose to 89.7 % from 88.2 %.
The rehabilitation segment continued to see planned reductions. During the reporting period, the bed capacity dropped from 1,569 beds last year to now 1,478 beds at a total of 10 facilities. In conjunction with this development, the capacity utilization quota for the year overall could be increased. The quota rose from last year´s 74.2 % to 75.9 % in FY 2006/07. Revenues also improved in the rehabilitation segment - from EUR 47.7 million to 48.3 million during the reporting period. The DVFA/SG-result (IFRS) was improved and came in at EUR -2.2 million (EUR -3.6 million in 2005/06). This represents an increase of 1.4 million thanks to the higher capacity utilization quota.
The company anticipates that it will continue to enjoy positive effects in its business divisions during the current fiscal year. The capacity reduction in the rehabilitation area translated into a significant increase of capacity utilization to approximately 87 % (previous year 76.7 %) even during the first quarter. The expansion in patient care continues at a rapid pace. In the first few months of the new fiscal year, the company has added 310 beds to the network and has again achieved substantial boosts in the capacity utilization quota of its existing facilities to 93.7 % in the first quarter (year prior 92.6 %). In the current fiscal year, thanks to additional capacities in the care segment and the occupancy rates of the existing bed capacity in both divisions - care and rehabilitation - , the company anticipates a substantial boost in revenues to EUR 240.0 million and a before-adjustments EBIT of EUR 24.0 million. Due to corporate tax reforms, latent tax accrual that had been accumulated in the past for a total of EUR 4.5 million could be liquidated to affect the statement net income. The result after taxes will amount to at least EUR 18 million.
In the new fiscal year 2007/2008, the care concept in the 2-star segment and the expansion of "Assisted Living" will be the focus of the expansion strategy. The company continues to remain committed to its growth goal of attaining a contractually vested total bed capacity of 12,000 by end of 2008.
End of the ad hoc release
end of announcement euro adhoc 10.10.2007 07:34:41
Further inquiry note:
Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin, Germany
Tel.: +49-30/24632-400
Fax: +49-30/24632-401
www.marseille-kliniken.com
Hillermann Consulting
Christian Hillermann
Investor Relations Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg, Germany
Tel.: +49-40/320279-10
Fax: +49-40/320279-14
www.hillermann-consulting.com
Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / official dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hamburg / official dealing